Canadian Cancer Trials Group Bulletins

Trial Management Group


Trial Closed to Accrual / Trial Permanently Closed

SRC.7/Alliance A091105 - A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumours or Aggressive Fibromatosis

Alliance suspended this study to further accrual on January 4, 2016. On December 1, 2016 Alliance announced that this study has met its accrual goal; therefore, as of December 1, 2016 at 5:00 PM ET, this study was permanently closed to new patient accrual.

Thank you to all participating sites and staff and patients for contributing to this study.
________________________________________

REC.1/CALGB 90206 - A Phase III Trial of Interferon-Alpha (IFNA) or IFNA Plus Bevacizumab in Advanced Renal Cell Cancer

We have received notification from the lead group that the REC.1/CALGB 90206 has been terminated/ permanently closed.

Please note that this trial no longer requires action, including the cessation of all patient follow-up for trial purposes, completion of Case Report Forms, and obtaining annual REB re-approvals. Any documentation submitted to CCTG for this trial will not be accepted and will be returned to sites.